CVX Carvolix SA

EPA · FR · Healthcare · Medical Devices · carvolix.eu

5.640EUR-2.42%Mkt Cap: 381.51M $P/E: —Today

Carvolix SA, a medical technology company, develops and markets minimally invasive, minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mecha…

Industry Peers

Medical Devices

Screen all

ABT

Abbott Laboratories Common Stock

$169.83BUSDP/E 31.6

MDT

Medtronic plc. Ordinary Shares

$110.49BUSDP/E 21.2

SYK

Stryker Corporation Common Stock

$105.65BUSDP/E 28.5

BSX

Boston Scientific Corporation Common Stock

$61.74BUSDP/E 17.2

Edwards Lifesciences Corporation Common Stock

$49.03BUSDP/E 50.7

SHL

Siemens Healthineers AG

$46.06BUSDP/E 19.2

DXCM

DexCom, Inc. - Common Stock

$32.21BUSDP/E 33.7

GEHC

GE HealthCare Technologies Inc. - Common Stock

$29.24BUSDP/E 14.8

PHG

Koninklijke Philips N.V. NY Registry Shares

$23.38BUSDP/E 18.5

PHIA

Koninklijke Philips N.V.

$22.58BUSDP/E 18.5

STE

STERIS plc (Ireland) Ordinary Shares

Zimmer Biomet Holdings, Inc. Common Stock

$16.84BUSDP/E 21.4

PEN

Penumbra, Inc. Common Stock

$12.51BUSDP/E 77.8

TXG

10x Genomics, Inc. - Common Stock

$12.18BUSD

SNN

Smith & Nephew SNATS, Inc. Common Stock

$11.06BUSDP/E 18.0

GMED

Globus Medical, Inc. Class A Common Stock

Bio-Rad Laboratories, Inc. Class A Common Stock

$9.88BUSDP/E 45.0

GKOS

Glaukos Corporation Common Stock

$9.66BUSD

Key Statistics

Company

Market Cap381.51M USD

Enterprise Value—

Revenue (TTM)1.73M USD

Gross Profit930.43K USD

Net Income (TTM)-16.02M USD

Revenue/Share0.02 EUR

Last Price5.640 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees59

CountryFR

SectorHealthcare

IndustryMedical Devices

ISINFR0013333077

Valuation

P/E (Trailing)—

P/E (Forward)-12.71

PEG—

EV/EBITDA—

EV/Revenue—

P/S226.23

P/B39.59

EPS (TTM)-0.64

EPS (Forward)-0.45

52W Range

1.32069% of range7.560

52W High7.560 EUR

52W Low1.320 EUR

Profitability

Gross Margin20.79%

Oper. Margin-1140.02%

EBITDA Margin0.00%

Profit Margin-357.92%

ROE-48.69%

ROA-24.22%

Growth

Revenue Growth119.60%

Earnings Growth—

Cash Flow & Leverage

Operating CF-12.31M USD

CapEx (TTM)159.78K USD

FCF Margin—

FCF Yield—

Net Debt—

Net Debt/EBITDA—

Balance Sheet

Debt/Equity0.54

Current Ratio—

Quick Ratio—

Book Value/Sh0.15 EUR

Cash/Share—

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 EUR

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.5 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)8.775 EUR

Upside (mean)+55.6%

Target Range6.000 EUR – 11.00 EUR

6.000+55.6% to mean11.00

# Analysts4

Ownership

Shares Out.62.23M

Float6.52M

Insiders18.27%

Institutions65.62%

Technical

SMA 505.986 (-5.8%)

SMA 2003.981 (+41.7%)

Beta—

S&P 52W Chg14.58%

Avg Vol (30d)32.84K

Avg Vol (10d)18.96K

Technical Indicators

RSI (14)49.3

MACD-0.0740

MACD Signal-0.0804

MACD Hist.+0.0064

BB Upper5.952 EUR

BB Middle5.743 EUR

BB Lower5.534 EUR

BB Width7.28%

ATR (14)0.2422 EUR

Vol Ratio (20d)1.52x